Study Evaluating HKI-272 Administered to Healthy Subjects

Puma Biotechnology

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: neratinib

Study type: Interventional

Funder types: Industry

Identifiers

NCT00366600

3144A1-107

Details and patient eligibility

About

Safety and tolerability of HKI-272 in healthy subjects; the influence of food intake on the same.

Enrollment: 56 patients

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Healthy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)